Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Retatrutide (LY3437943) is an investigational medicinal product (IMP) a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors currently under clinical evaluation for obesity and metabolic disease
These include next-generation GLP-1s, such as retatrutide, as well as GLP-1 combination drugs, like cagrilintide with semaglutide
In rare cases, it can be a sign of pancreatitis, which needs prompt medical attention
This article explains why peptide medicines like retatrutide are challenging to deliver orally, where retatrutide currently sits in its clinical development programme, and which licensed weight management medicines are available in the UK today
.png)
US$ 29.32
US$ 24.23
US$ 22.53
US$ 23.38
US$ 21.17
